Agreement - June 4, 2019
Xbrane enters term-sheet with STADA
The company has entered a non-binding term-sheet with STADA Arzneimittel for cooperation regarding sales and marketing of Spherotide for Europe, and furthermore, the company updates on its plans to take the product into a phase III study in endometriosis patients. Non-binding term-sheet with STADA The company´s non-binding term-sheet with STADA consists of an agreement to […]
Collaboration - May 31, 2019
STADA and Xbrane strengthen collaboration
The two companies have expanded their strategic biosimilar development partnership, which allows both companies to evaluate potential development and commercialization collaborations around Xbrane’s Xcimzane and Xdivane preclinical biosimilars and additional biosimilars that fit both companies’ portfolios. “This partnership is a great opportunity for STADA to accelerate the expansion of our biosimilar portfolio and to strengthen our market […]
Biotech Business - October 5, 2015
Xbrane acquires Primm Pharma
Xbrane has acquired the Italian based Primm Pharma and completed a distribution deal with the Iranian company Pooyesh Darou. Xbrane is a commercial phase Swedish biopharmaceutical company specialized in High Demand Complex Generics. Primm Pharma specializes in the development and production of pharmaceutical formulations for slow release injections and has a portfolio currently consisting of […]
